Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APL-1202 in Relapsed High-Risk NMIBC
NCT04498702Phase 2Completed
- Sponsor
- Asieris Pharmaceuticals
- Start
- May 2014
- Primary completion
- Jan 2017
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of APL-1202 + APL-1501 in non-muscle-invasive bladder cancer (NMIBC), sponsored by Asieris Pharmaceuticals. Started May 2014; status: completed.
02
Drugs
APL-1202 + APL-1501
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT04498702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04498702.